Michele Curatolo, MD, PhD
@michelecuratolo.bsky.social
300 followers
260 following
20 posts
Physician, scientist, teacher, and leader in pain medicine. Professor at the University of Washington. Italian and Swiss. http://michelecuratolomd.com.
Posts
Media
Videos
Starter Packs
Pinned
Reposted by Michele Curatolo, MD, PhD
Reposted by Michele Curatolo, MD, PhD
Reposted by Michele Curatolo, MD, PhD
Ted Price
@tedpricethepainguy.bsky.social
· Aug 16
Deciphering the molecular landscape of human peripheral nerves: implications for diabetic peripheral neuropathy
Diabetic peripheral neuropathy (DPN) is a prevalent complication of diabetes mellitus that is caused by metabolic toxicity to peripheral axons. We aimed to gain deep mechanistic insight into the disea...
www.biorxiv.org
Reposted by Michele Curatolo, MD, PhD
Reposted by Michele Curatolo, MD, PhD
Reposted by Michele Curatolo, MD, PhD
Ted Price
@tedpricethepainguy.bsky.social
· Apr 15
Reposted by Michele Curatolo, MD, PhD
Reposted by Michele Curatolo, MD, PhD
Ted Price
@tedpricethepainguy.bsky.social
· Mar 31
Ted Price
@tedpricethepainguy.bsky.social
· Mar 27
Human sensory neurons exhibit cell-type-specific, pain-associated differences in intrinsic excitability and expression of SCN9A and SCN10A
Despite the prevalence of chronic pain, the approval of novel, non-opioid therapeutics has been slow. A major translational challenge in analgesic development is the difference in gene expression and ...
www.biorxiv.org
Reposted by Michele Curatolo, MD, PhD
Eric Topol
@erictopol.bsky.social
· Mar 26
A broad-spectrum lasso peptide antibiotic targeting the bacterial ribosome - Nature
A new lasso peptide antibiotic exhibits broad-spectrum activity against Gram-negative and Gram-positive bacteria by interfering with bacterial protein synthesis, is unaffected by common resistanc...
www.nature.com
Reposted by Michele Curatolo, MD, PhD
Robert Gereau
@robgereau.bsky.social
· Mar 5
A cryptic pocket in CB1 drives peripheral and functional selectivity - Nature
A peripherally restricted CB1 agonist (VIP36) targeting a cryptic receptor pocket was developed, showing high efficacy in mouse pain models with minimal side effects and tolerance, potentially revolut...
www.nature.com
Reposted by Michele Curatolo, MD, PhD